News - New Director
Covalent Group, Inc. Appoints Distinguished Clinical and Research Oncologist To the Board of Directors
WAYNE, Pa., May 10, 2000 -- Covalent Group, Inc. (Nasdaq: CVGR) today announced that Stephen E. Sallan, M.D., Professor of Pediatrics at Harvard Medical School and Chief-of-Staff at the Dana-Farber Cancer Institute in Boston, has been named to its Board of Directors. The appointment of Dr. Sallan increases Board membership to five, three of which are non-employee directors.
Dr. Sallan is a prominent and award-winning physician. He is the Firm Chief of Oncology and Chairman of the Investigational Review Board at the Dana-Farber Cancer Institute, Vice Chair for Clinical Research at Children's Hospital in Boston, and a member of the Scientific Advisory Board at the St. Jude Children's Research Hospital in Memphis, Tennessee. He is one of the world's foremost experts on childhood leukemia. His research has led to the highly innovative and successful bone marrow transplantation program pioneered at Dana-Farber Cancer Institute. Dr. Sallan has authored more than 250 scientific publications and book chapters and is a member of numerous prominent national committees and societies. Among his many honors, Dr. Sallan was the first recipient of the Sir James Carreras Award of Variety Clubs International in recognition of his outstanding contributions to pediatric medicine.
Kenneth M. Borow, M.D., Chief Executive Officer of Covalent said, "We are extremely pleased to welcome Dr. Sallan to our Board of Directors. He brings a wealth of experience to Covalent and is one of the world's recognized thought leaders in oncology. Dr. Sallan and his network of contacts within all aspects of cancer research fit well into Covalent's business plan for advanced consultative services in drug, biotechnology and device development.".... |
